
Bluebird bio shares fall amid acquisition woes
Investing.com -- Shares of Bluebird bio Inc (NASDAQ:BLUE) tumbled 8% in premarket trading today following the company’s confirmation that Ayrmid, Ltd. has not delivered a binding offer or secured the necessary financing for a potential acquisition. The biotechnology firm’s board has reiterated its recommendation for shareholders to support the existing transaction with Carlyle and SK Capital ...